Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%.
Pfizer Inc. (NYSE:PFE) is a major US pharmaceutical and biotechnology company that offers a wide range of products and services. In recent years, the company has experienced declining revenue and profits, leading to a significant drop in its market value. While Pfizer has been working to reverse this trend, progress has been limited so far.
Pfizer Inc. (NYSE:PFE) has focused on launching new drugs to drive top-line growth. Recently, the company announced a $5 billion cash acquisition of Metsera, a smaller biotech firm developing weight management treatments. Some of Pfizer’s internally developed candidates in this area have been unsuccessful, but the growing market for anti-obesity therapies presents an opportunity. The company also maintains a robust pipeline in oncology, with several candidates expected to receive approval over time.
In addition, Pfizer Inc. (NYSE:PFE) dividend yield remains a strong attraction for investors, adding to its appeal as an income-generating stock. The stock supports a dividend yield of 6.94%, as of October 12. The company has raised its dividends for 15 consecutive years and currently offers a quarterly dividend of $0.43 per share.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Most Promising Dividend Stocks According to Wall Street Analysts and Top 15 Dividend Growth Stocks for Long-Term Investors
Disclosure: None.